Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus

Abstract

Introduction

We examined the clinical relevance of urinary concentrations of B-cell–activating factor of the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) in systemic lupus erythematosus (SLE).

Methods

We quantified urinary BAFF (uBAFF) by enzyme-linked immunosorbent assay in 85 SLE, 28 primary Sjögren syndrome (pSS), 40 immunoglobulin A nephropathy (IgAN) patients and 36 healthy controls (HCs). Urinary APRIL (uAPRIL) and monocyte chemoattractant protein 1 (uMCP-1) were also quantified. Overall and renal SLE disease activity were assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000.

Results

uBAFF was detected in 12% (10/85) of SLE patients, but was undetectable in HCs, IgAN and pSS patients. uBAFF was detectable in 28% (5/18) of SLE patients with active nephritis vs 5/67 (7%) of those without (p = 0.03), and uBAFF was significantly higher in active renal patients (p = 0.02) and more likely to be detected in patients with persistently active renal disease. In comparison, uAPRIL and uMCP-1 were detected in 32% (25/77) and 46% (22/48) of SLE patients, respectively. While no difference in proportion of samples with detectable uAPRIL was observed between SLE, HCs and IgAN patients, both uAPRIL and uMCP-1 were significantly detectable in higher proportions of patients with active renal disease.

Conclusions

uBAFF was detectable in a small but a significant proportion of SLE patients but not in other groups tested, and was higher in SLE patients with active renal disease.

Keywords

A proliferation-inducing ligand (APRIL)B-cell–activating factor from the tumour necrosis factor family (BAFF)biomarker lupus nephritis (LN)monocyte chemoattractant protein 1 (MCP-1)systemic lupus erythematosus (SLE)

Get full access to this article

View all access options for this article.

References

Lisnevskaia

Murphy

Isenberg

. Systemic lupus erythematosus. Lancet 2014; 384: 1878–1888.

Wahren-Herlenius

Dörner

. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 2013; 382: 819–831.

Vincent

Morand

Schneider

Mackay

. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 2014; 10: 365–373.

Mackay

Woodcock

Lawton

et al.

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697–1710.

Vincent

Saulep-Easton

Figgett

Fairfax

Mackay

. The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 2013; 24: 203–215.

Mariette

Roux

Zhang

et al.

The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 2003; 62: 168–171.

Gottenberg

Seror

Miceli-Richard

et al.

Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One 2013; 8: e59868.

Quartuccio

Salvin

Fabris

et al.

BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford) 2013; 52: 276–281.

Steri

Orrù

Idda

et al.

Overexpression of the cytokine BAFF and autoimmunity risk. N Engl J Med 2017; 376: 1615–1626.

10.

Navarra

Guzmán

Gallacher

et al.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721–731.

11.

Furie

Petri

Zamani

et al.

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918–3930.

12.

Cheema

Roschke

Hilbert

Stohl

. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313–1319.

13.

Vincent

Northcott

Hoi

Mackay

Morand

. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. Lupus 2013; 22: 873–884.

14.

Phatak

Chaurasia

Mishra

et al.

Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): Potential biomarkers of active lupus nephritis. Clin Exp Immunol 2017; 187: 376–382.

15.

Neusser

Lindenmeyer

Edenhofer

et al.

Intrarenal production of B-cell survival factors in human lupus nephritis. Mod Pathol 2011; 24: 98–107.

16.

Sun

Shen

Chen

et al.

The characteristics and significance of locally infiltrating B cells in lupus nephritis and their association with local BAFF expression. Int J Rheumatol 2013; 2013: 954292.

17.

Abujam

Cheekatla

Aggarwal

. Urinary CXCL-10/IP-10 and MCP-1 as markers to assess activity of lupus nephritis. Lupus 2013; 22: 614–623.

18.

Rosa

Takei

Araújo

Loduca

Szajubok

Chahada

. Monocyte chemoattractant-1 as a urinary biomarker for the diagnosis of activity of lupus nephritis in Brazilian patients. J Rheumatol 2012; 39: 1948–1954.

19.

Singh

Usha Rathore

Behura

Singh

. Urinary MCP-1 as diagnostic and prognostic marker in patients with lupus nephritis flare. Lupus 2012; 21: 1214–1218.

20.

Herbst

Liu

Jallal

Yao

. Biomarkers for systemic lupus erythematosus. Int J Rheum Dis 2012; 15: 433–444.

21.

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725. doi:10.1002/art.1780400928.

22.

Vincent

Northcott

Hoi

Mackay

Morand

. Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res Ther 2013; 15: R97.

23.

Pitashny

Schwartz

Qing

et al.

Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum 2007; 56: 1894–1903.

24.

Franklyn

Lau

Navarra

et al.

Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 2016; 75: 1615–1621.

25.

Petri

Kim

Kalunian

et al.

Combined oral contraceptives in women with systemic lupus erythematosus. New Engl J Med 2005; 353: 2550–2558.

26.

Mende

Vincent

Kandane-Rathnayake

et al.

Analysis of serum interleukin (IL)-1beta and IL-18 in systemic lupus erythematosus. Front Immunol 2018; 9: 1250.

27.

Weening

D'Agati

Schwartz

et al.

The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241–250.

28.

Stoll

Seifert

Isenberg

. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996; 35: 248–254.

29.

Vitali

Bombardieri

Jonsson

et al.

Classification criteria for Sjögren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554–558.

30.

Brown

Nikolic-Paterson

Hill

et al.

Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis. J Am Soc Nephrol 2002; 13(Suppl 1): S7–S13.

31.

Korbet

Lewis

Collaborative Study Group . Complete remission in severe lupus nephritis: Assessing the rate of loss in proteinuria. Nephrol Dial Transplant 2012; 27: 2813–2819.

32.

Noris

Bernasconi

Casiraghi

et al.

Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 1995; 73: 804–809.

33.

Wada

Yokoyama

et al.

Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996; 49: 761–767.

34.

El-Shehaby

Darweesh

El-Khatib

et al.

Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol 2011; 31: 848–856.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.22 MB